Volume 1, Issue 1 (Vaccine Research 2014)                   vacres 2014, 1(1): 21-24 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Daemi A, Hosseinzadeh S, Bolhassani A, Agi E. DNA-Based Vaccine Is More Efficient than Non-Pathogenic Live Vaccine for the Prevention of HPV16 E7-Overexpressing Cancers. vacres 2014; 1 (1) :21-24
URL: http://vacres.pasteur.ac.ir/article-1-30-en.html
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (9056 Views)

  Introduction: Vaccinology provides promising approaches for the control of various infectious diseases. Among different strategies, DNA vaccines offer attractive research opportunities for development of vaccines for induction of antigen-specific immunity owing to their stability, simplicity of delivery, safety and cost effectiveness. However, there is a need to increase their potency by the use of adjuvants such as glycoprotein 96 and electroporation delivery. On the other hand, the attenuated or non-pathogenic live vectors have been used to deliver DNA into cells as efficient delivery tools in gene therapy. Recently, a non-pathogenic protozoan, Leishmania tarentolae (L. tar), has attracted attention as an in situ protein-delivery vehicle. Cervical cancer is the second largest cause of cancer deaths among women worldwide and human papillomaviruses (HPV) is reportedly a frequent cause of this type of cancer. Methods: In the current study, we compared the potential of live L. tar-based and DNA-based vaccines expressing HPV16 E7 linked to C-terminal fragment of gp96 in a tumor mouse model. Results: We found that subcutaneous DNA injection with E7-CT (gp96), followed by electroporation, generate a significant E7-specific IFN-γ immune response and in vivo protective effects compared to transgenic L. tar-E7-CT (gp96) in challenge experiments with TC-1. Conclusion: It could be concluded that the DNA vaccine showed higher efficacy compared to the non-pathogenic live parasite-based vaccine in the tumor mice model. Vac Res , 2014, 1 (1): 22-25

Full-Text [PDF 696 kb]   (2253 Downloads)    
Type of Study: Original article |
Received: 2013/10/6

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.